Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
877.79
-31.53 (-3.47%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
July 13, 2024
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.
Via
The Motley Fool
SPDR ETF Report For Friday, July 12
July 13, 2024
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, July 12.
Via
Talk Markets
Topics
ETFs
The Next Trillion-Dollar Stocks? 3 Top Contenders to Buy Now
July 12, 2024
These potential trillion dollar stocks are the next companies poised to join the elite club and drive future market growth.
Via
InvestorPlace
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
July 12, 2024
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
Via
Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
July 12, 2024
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate...
Via
Benzinga
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
July 12, 2024
Via
Benzinga
Eli Lilly Announces CFO Change
July 10, 2024
Shares of Eli Lilly And Company (NYSE: LLY) are moving higher on Wednesday. Here's what you need to know.
Via
Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
July 09, 2024
Via
Benzinga
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
July 12, 2024
A yearlong study at the University of Oxford suggests GLP-1 drugs could play a role in protecting brain health.
Via
Investor's Business Daily
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
July 12, 2024
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory risks. New warnings to be included in product information to ensure...
Via
Benzinga
Should You Buy Eli Lilly Stock After Another Major Win?
July 12, 2024
It was a buy even before this development.
Via
The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
July 12, 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment.
Via
InvestorPlace
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
July 12, 2024
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.
Via
Benzinga
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
July 11, 2024
JUPITER, Fla. - July 11, 2024 - PRLog -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum...
Via
PRLog
Exposures
Product Safety
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
July 11, 2024
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Via
Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
July 11, 2024
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations.
Via
Benzinga
3 Future Blue-Chip Stocks That Could Make You Rich
July 11, 2024
Blue-chip stocks are the cream of the crop of the stock exchange market. Find out about the best future blue-chip stocks to invest in.
Via
InvestorPlace
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
July 11, 2024
Both equities have been incredible growth plays of late.
Via
The Motley Fool
Topics
ETFs
Warren Buffett Recommends This Magnificent Index Fund. It Could Turn $500 Per Month Into $986,900
July 11, 2024
The S&P 500 is a group of businesses that are bound to perform well over time, according to Warren Buffett.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
July 11, 2024
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's Tesla, and Eli Lilly.
Via
Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
July 10, 2024
Investors might want to consider the top pharma stocks in the current environment as they are beating most others.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
July 10, 2024
Via
Benzinga
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
July 10, 2024
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on the medication after two years, raising concerns about long-term adherence.
Via
Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
July 09, 2024
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to...
Via
Benzinga
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion – InsideArbitrage
July 09, 2024
Via
AB Newswire
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
July 09, 2024
Give some consideration to these names, each of which has a strong competitive advantage and catalysts driving their share price higher.
Via
InvestorPlace
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
July 09, 2024
Want to turn your $10K into $1 million? Here are three high-growth potential stocks that can make it happen for you.
Via
InvestorPlace
Summer 2024 Snapshot Of The S&P 500's Market Cap
July 09, 2024
The market capitalization of the S&P 500 grew by 4.2% during the course of the second quarter of 2024. The index ended 2024-Q2 with a market cap of $47.83 trillion according to Standard and Poor.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
July 09, 2024
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been
Via
MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
July 09, 2024
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.
Via
InvestorPlace
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.